Abstract
Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyricline (a P2Y12 receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyricline derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y12 receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1627-1633 |
| Number of pages | 7 |
| Journal | Expert Opinion on Investigational Drugs |
| Volume | 15 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2006 |
Fingerprint
Keywords
- Non-responsiveness
- Platelet inhibition
- Prasugrel
- Thienopyridine
ASJC Scopus subject areas
- Pharmacology
Cite this
Prasugrel. / Tantry, Udaya S.; Bliden, Kevin P.; Gurbel, Paul A.
In: Expert Opinion on Investigational Drugs, Vol. 15, No. 12, 12.2006, p. 1627-1633.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prasugrel
AU - Tantry, Udaya S.
AU - Bliden, Kevin P.
AU - Gurbel, Paul A.
PY - 2006/12
Y1 - 2006/12
N2 - Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyricline (a P2Y12 receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyricline derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y12 receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.
AB - Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyricline (a P2Y12 receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyricline derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y12 receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.
KW - Non-responsiveness
KW - Platelet inhibition
KW - Prasugrel
KW - Thienopyridine
UR - http://www.scopus.com/inward/record.url?scp=33845224320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845224320&partnerID=8YFLogxK
U2 - 10.1517/13543784.15.12.1627
DO - 10.1517/13543784.15.12.1627
M3 - Article
C2 - 17107286
AN - SCOPUS:33845224320
VL - 15
SP - 1627
EP - 1633
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
SN - 1354-3784
IS - 12
ER -